Is There a Phase 3 Trial of Riosa-Gua in PAH-F PEPF?

Based on the results of dynamic, do you think that there will be a phase 3 trial with Riosa-Gua in PAH-F PEPF? And how may the subgroup of patients with HEPF be best defined that may profit from SGC simulators or PDE5 inhibitors such as Siltenafil or Tadalafil? Well, as stated above from a clinical point and a pedophysiological point of view, these should be well-characterized CPCPH patients. Currently, only amp-barkly fluency is approved for HEPF, but at the main EAC Congress in August in Barcelona, data from the liver study with top